cyc 202 has been researched along with purvalanol b in 8 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (purvalanol b) | Trials (purvalanol b) | Recent Studies (post-2010) (purvalanol b) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 31 | 0 | 13 |
| Protein | Taxonomy | cyc 202 (IC50) | purvalanol b (IC50) |
|---|---|---|---|
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.006 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.009 | |
| Cyclin-dependent kinase 1 | Saccharomyces cerevisiae S288C | 1.2 | |
| Insulin receptor | Homo sapiens (human) | 2.2 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.006 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.006 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.006 | |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 0.006 | |
| cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | 3.8 | |
| Cyclin-A2 | Homo sapiens (human) | 0.006 | |
| cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | 3.8 | |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | 3.8 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.009 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0072 | |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | 3.3165 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.006 | |
| Cyclin-A1 | Homo sapiens (human) | 0.006 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.006 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.006 | |
| Cdc2 | Patiria pectinifera | 0.15 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.006 | |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benfield, PA; Boylan, JF; Sielecki, TM; Trainor, GL | 1 |
| Ducrot, P; Endicott, J; Grierson, DS; Legraverend, M; Leost, M; Ludwig, O; Meijer, L; Noble, M; Tunnah, P | 1 |
| Matter, H; Naumann, T | 1 |
| Brown, ML; Dakshanamurthy, S; Deb, TB; Grindrod, SC; Paige, M; Yang, Y; Yenugonda, VM | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Doerig, C; Gray, N; Harmse, L; Havlik, I; Leclerc, S; Meijer, L; Schultz, P; van Zyl, R | 1 |
| Bantly, A; Gray, NS; Knockaert, M; Malim, MH; Meijer, L; Schaffer, PA; Schang, LM; Shaheen, F | 1 |
| Arisan, ED; Coker-Gurkan, A; Obakan-Yerlikaya, P; Ozfiliz-Kilbas, P; Palavan-Unsal, N; Sarikaya, B; Temizci, B | 1 |
1 review(s) available for cyc 202 and purvalanol b
| Article | Year |
|---|---|
Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation.
Topics: Animals; Cell Cycle; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Models, Molecular | 2000 |
7 other study(ies) available for cyc 202 and purvalanol b
| Article | Year |
|---|---|
Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.
Topics: Adenine; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Crystallography, X-Ray; Cyclin B; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Protein Serine-Threonine Kinases; Purines; Roscovitine; Structure-Activity Relationship | 2000 |
Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes.
Topics: Binding Sites; Crystallography, X-Ray; Cyclin-Dependent Kinases; Enzyme Inhibitors; Ligands; Models, Molecular; Molecular Structure; Purines; Quantitative Structure-Activity Relationship | 2002 |
Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Topics: Adenine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Dansyl Compounds; Female; Fluorescent Dyes; Humans; Protein Kinase Inhibitors | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum.
Topics: Adenine; Animals; Antimalarials; Cell Cycle; Dose-Response Relationship, Drug; Isopentenyladenosine; Kinetin; Parasitic Sensitivity Tests; Phosphotransferases; Plasmodium falciparum; Purines; Roscovitine; Structure-Activity Relationship | 2001 |
Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.
Topics: Adenine; Animals; Antiviral Agents; Cell Cycle; Cell Line; Chlorocebus aethiops; Cyclin-Dependent Kinases; Drug Resistance, Viral; Enzyme Inhibitors; HIV-1; Humans; Purines; Roscovitine; Simplexvirus; Vero Cells; Viral Proteins; Virus Replication | 2002 |
Cyclin-dependent kinase inhibitors, roscovitine and purvalanol, induce apoptosis and autophagy related to unfolded protein response in HeLa cervical cancer cells.
Topics: Adenine; Autophagy; Cell Proliferation; Cell Survival; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Protein Kinase Inhibitors; Purines; Reactive Oxygen Species; Roscovitine; Time Factors; Unfolded Protein Response; Uterine Cervical Neoplasms | 2018 |